Thermo Fisher Scientific Gibco CTS OpTmizer Pro Serum Free Media (SFM)

Wednesday, 10 February, 2021 | Supplied by: Thermo Fisher Scientific


Thermo Fisher Scientific has developed a medium for the development and expansion of human T lymphocytes (T cells) for cell therapy developers using allogeneic workflows. The Gibco CTS OpTmizer Pro Serum Free Media (SFM) is a media solution that targets the metabolism of healthy donor cells, making it suitable for use in the production of allogeneic, off-the-shelf cell therapies.

In contrast to autologous cell therapies, which are produced using a patient’s own cells, allogeneic cell therapies are derived from healthy donor tissue, potentially enabling more scalable cell therapy manufacturing. The SFM enhances donor T cell proliferation, maintains central memory T cells further into expansion and delays effector differentiation of healthy donor T cells, resulting in fast production of central memory cells.

The product packaging is suitable for closed systems and is manufactured in conformity with current Good Manufacturing Practice (cGMP) standards. The serum-free media is ready to use and compatible with automated and long workflows, providing a consistent formulation designed to maintain cell quality and increase the efficacy of cell-based therapies.

Online: thermofisher.com
Phone: 1300 735 292
Related Products

Biosensis MAP2 antibodies

Biosensis's validated MAP2 antibodies are designed to help users identify MAP2, whether they...

Bio-Rad Laboratories Celselect Slides validated antibodies for rare cell and CTC enumeration

The antibodies are specific to CTC surface markers to enable the sensitive and specific...

Microbiologics UV-BioTAG QC microorganisms for quality control testing

UV-BioTAG, a line of reference strains containing green fluorescent protein (GFP) markers, makes...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd